ACR-ABS-ASTRO Practice Parameter for the Performance of Low-Dose-Rate Brachytherapy

Kristina D. Woodhouse, Phillip M. Devlin, Marisa Kollmeier, Lilie L. Lin, Peter Orio, Zoubir Ouhib, Daniel Song, Akila N. Viswanathan, Yoichi Watanabe, Yan Yu, William Small, Naomi R. Schechter

Research output: Contribution to journalArticlepeer-review

Abstract

Aim/Objectives/Background: The American College of Radiology (ACR), the American Brachytherapy Society (ABS), and the American Society for Radiation Oncology (ASTRO) have jointly developed the following practice parameter for the performance of low-dose-rate (LDR) brachytherapy. LDR brachytherapy is the application of radioactive sources in or on tumors in a clinical setting with therapeutic intent. The advantages of LDR brachytherapy include improving therapeutic ratios with lower doses to nontarget organs-at-risk and higher doses to a specific target. Methods: This practice parameter was developed according to the process described under the heading. The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website (https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards) by the Committee on Practice Parameters - Radiation Oncology of the Commission on Radiation Oncology, in collaboration with ABS and ASTRO. Results: This practice parameter was developed to serve as a tool in the appropriate application of this evolving technology in the care of cancer patients or other patients with conditions where radiation therapy is indicated. It addresses clinical implementation of LDR brachytherapy including personnel qualifications, quality assurance standards, indications, and suggested documentation. This includes a contemporary literature search. Conclusions: This practice parameter is a tool to guide the use of LDR brachytherapy and does not assess relative clinical indication for LDR brachytherapy when compared with other forms of brachytherapy or external beam therapy, but to focus on the best practices required to deliver LDR brachytherapy safely and effectively, when clinically indicated. Comparative costs of versus other modalities therapy may also need to be considered.

Original languageEnglish (US)
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
DOIs
StateAccepted/In press - 2022

Bibliographical note

Funding Information:
L.L.L. reports grants from National Cancer Institute, other from Astrazeneca, other from Pfizer, outside the submitted work. P.O. reports personal fees from Palette Life Sciences, outside the submitted work. D.S. reports grants from the National Cancer Institute, outside the submitted work. W.S. reports personal fees from Carl Zeiss Meditech, personal fees from Merck, personal fees from Varian, grants from University of Utah, other from NRG Oncology, outside the submitted work. The remaining authors declare no conflicts of interest.

Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.

Keywords

  • brachytherapy
  • bronchial lesions
  • cancer
  • esophageal lesions
  • low-dose-rate brachytherapy
  • obstructive bile duct lesions
  • radiation safety
  • radionuclides
  • treatment goals
  • treatment planning

PubMed: MeSH publication types

  • Journal Article
  • Practice Guideline
  • Research Support, Non-U.S. Gov't

Fingerprint

Dive into the research topics of 'ACR-ABS-ASTRO Practice Parameter for the Performance of Low-Dose-Rate Brachytherapy'. Together they form a unique fingerprint.

Cite this